The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.
October 19th 2021
The availability of chemoimmunotherapy combinations and targeted agents for common and rare mutations alike in non–small cell lung cancer has fostered discussions that might have been unthinkable just a decade or so ago.
October 4th 2021
Miranda Gogishvili, MD, discusses the rationale for examining cemiplimab plus platinum-doublet chemotherapy as a frontline treatment in patients with advanced NSCLC and key findings from the phase 3 EMPOWER-Lung 3 trial.
September 20th 2021
Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.
July 31st 2021
Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.
June 30th 2021
Drs Roy S. Herbst and Sandip P. Patel comment on patient candidacy for immunotherapy as monotherapy to treat PD-L1+ metastatic non–small cell lung cancer versus chemoimmunotherapy.
June 30th 2021
Roy S. Herbst, MD, PhD, of Yale Cancer Center, highlights treatment advances in stage IV non–small cell lung cancer, including cemiplimab as frontline monotherapy based on EMPOWER-Lung 1.
June 28th 2021
Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, cover the latest results with neoadjuvant immunotherapy strategies that were highlighted at the 2021 ASCO Annual Meeting.
June 4th 2021
The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.
May 28th 2021
The investigational PD-L1 inhibitor sugemalimab prolonged progression-free survival in patients with locally advanced, unresectable stage III non–small cell lung cancer without disease progression after concurrent or sequential chemoradiation.
April 23rd 2021
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the combination of nivolumab and ipilimumab as a frontline treatment for adult patients with unresectable malignant pleural mesothelioma.
April 15th 2021
This publication reviews the role of single-agent and dual immunotherapy for the treatment of metastatic non-small-cell lung cancer, recapping key insights from a scientific interchange & workshop.
April 10th 2021
Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.
March 31st 2021
John V. Heymach, MD, PhD, discusses the future of immunotherapy in patients with non–small cell lung cancer.
March 27th 2021
More patients with stage III non–small cell lung cancer received sequential chemoradiation and delayed the time to durvalumab treatment in a real-world setting compared with those enrolled on the phase 3 PACIFIC trial.
March 25th 2021
First-line treatment with camrelizumab, an investigational PD-1 inhibitor, plus chemotherapy induced robust and durable clinical responses in patients with advanced squamous non–small cell lung cancer.
March 12th 2021
Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.
February 18th 2021
In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.
February 8th 2021
With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.
February 8th 2021
Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.